Focus: Elevar Therapeutics is a newly founded (2024) Seoul-based oncology-focused biotech company developing multi-asset pipeline targeting solid tumors and rare cancers. The company operates as a pre-revenue stage biotech with early-to-mid clinical programs.
Profile data last refreshed 9h ago · AI intelligence enriched 2mo ago
Stable — net +4 jobs in 30d
7 added, 3 removed. Backfill posture.
A speculative career move suitable only for biotech specialists seeking maximum upside in an unproven Seoul-based oncology startup with meaningful clinical assets but minimal operational scale.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Elevar Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Elevar Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Elevar Therapeutics to Share Camrelizumab/Rivoceranib - GlobeNewswire
Elevar Therapeutics to Share Camrelizumab/Rivoceranib GlobeNewswire
How 2 FDA citations complicate Hengrui, Elevar’s push for liver cancer combo approval - Fierce Pharma
How 2 FDA citations complicate Hengrui, Elevar’s push for liver cancer combo approval Fierce Pharma
Manufacturing issues prompt FDA to reject Hengrui-Elevar filings for third time - BioSpace
Manufacturing issues prompt FDA to reject Hengrui-Elevar filings for third time BioSpace
HLB resolves issues behind FDA setback for novel liver cancer drug - The Korea Times
HLB resolves issues behind FDA setback for novel liver cancer drug The Korea Times
FDA hurdle cleared for liver cancer drug application: HLB - The Korea Herald
FDA hurdle cleared for liver cancer drug application: HLB The Korea Herald
HLB group soars as FDA clears manufacturing for liver cancer drug in US - CHOSUNBIZ - Chosunbiz
HLB group soars as FDA clears manufacturing for liver cancer drug in US - CHOSUNBIZ Chosunbiz
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Impact of Age on Patient-Reported Outcomes with First-Line Camrelizumab plus Rivoceranib versus Sorafenib in Adults with Unresectable Hepatocellular Carcinoma: Post Hoc Analyses of the CARES-310 Open-Label, Randomized, Phase 3 Trial.
Phase 1/2a Study of Rivoceranib, a Selective VEGFR-2 Angiogenesis Inhibitor, in Patients with Advanced Solid Tumors.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo